[{"id":"113cfda4-7d09-419b-a619-1fc822fa3cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03088878","created_at":"2021-01-18T15:13:07.925Z","updated_at":"2025-02-25T15:17:25.790Z","phase":"Phase 1/2","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03088878","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/03/2018","start_date":" 01/03/2018","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2025-02-12"},{"id":"9d91719c-a4f8-489a-a4f8-f503e0f382e7","acronym":"PBL-0405-01","url":"https://clinicaltrials.gov/study/NCT06273852","created_at":"2024-02-23T16:26:42.227Z","updated_at":"2024-07-02T16:35:03.110Z","phase":"Phase 1","brief_title":"A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors","source_id_and_acronym":"NCT06273852 - PBL-0405-01","lead_sponsor":"Pure Biologics S.A.","biomarkers":" ROR1 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["ROR1 • TNFA • CASP3 • GZMB • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"a37af355-2625-4415-ae7c-59d702230ad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776917","created_at":"2021-01-18T13:37:02.048Z","updated_at":"2024-07-02T16:35:10.661Z","phase":"Phase 1","brief_title":"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer","source_id_and_acronym":"NCT02776917","lead_sponsor":"Barbara Parker, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 07/13/2021","primary_completion_date":" 07/13/2021","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-10"},{"id":"ddf0452e-32bb-460c-8ff8-6fa35814d73e","acronym":"GNC-035-103","url":"https://clinicaltrials.gov/study/NCT05160545","created_at":"2021-12-16T13:53:38.176Z","updated_at":"2024-07-02T16:35:21.629Z","phase":"Phase 1","brief_title":"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05160545 - GNC-035-103","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nebratamig (GNC-035)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/26/2021","start_date":" 11/26/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-01-31"},{"id":"b150f7b0-fa0a-4051-89d4-8cd9aed4ac61","acronym":"NVG111-101","url":"https://clinicaltrials.gov/study/NCT04763083","created_at":"2021-02-21T13:52:27.874Z","updated_at":"2024-07-02T16:35:43.724Z","phase":"Phase 1","brief_title":"First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies","source_id_and_acronym":"NCT04763083 - NVG111-101","lead_sponsor":"NovalGen Ltd.","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NVG-111"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/14/2021","start_date":" 05/14/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-07-07"},{"id":"ca421334-f9eb-4377-938c-37226f3e8745","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039931","created_at":"2021-09-10T16:57:17.104Z","updated_at":"2024-07-02T16:35:53.134Z","phase":"Phase 1","brief_title":"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05039931","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nebratamig (GNC-035)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2023-03-16"},{"id":"2825ea8b-9459-479e-9752-18cd9b5e3122","acronym":"","url":"https://clinicaltrials.gov/study/NCT02860676","created_at":"2021-01-18T14:02:32.507Z","updated_at":"2024-07-02T16:37:01.504Z","phase":"Phase 1","brief_title":"Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961","source_id_and_acronym":"NCT02860676","lead_sponsor":"University of California, San Diego","biomarkers":" CD19 • CD5","pipe":"","alterations":" ","tags":["CD19 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 11/03/2016","start_date":" 11/03/2016","primary_txt":" Primary completion: 02/27/2018","primary_completion_date":" 02/27/2018","study_txt":" Completion: 05/22/2018","study_completion_date":" 05/22/2018","last_update_posted":"2019-03-20"},{"id":"8ac1e017-da1c-4007-8416-53084f3ac3fb","acronym":"CIRLL study","url":"https://clinicaltrials.gov/study/NCT03420183","created_at":"2021-01-18T16:52:25.006Z","updated_at":"2024-07-02T16:37:02.627Z","phase":"Phase 1b","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03420183 - CIRLL study","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" ROR1","pipe":"","alterations":" ","tags":["ROR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2019-02-20"}]